Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Favipiravir  COVID-19 treatment studies for Favipiravir  C19 studies: Favipiravir  Favipiravir   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Melatonin (meta)
Aspirin (meta) Metformin (meta)
Bamlaniv../e.. (meta) Molnupiravir (meta)
Bebtelovimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Cannabidiol (meta) Nitric Oxide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)
Lactoferrin (meta)

Other Treatments Global Adoption
 
Favipiravir COVID-19 studies. Potential risks of the mechanism of action include the creation of dangerous variants, and mutagenicity, carcinogenicity, teratogenicity, and embryotoxicity [Hadj Hassine, Waters, Zhirnov]. Recent:
Usanma Koban
Tawfik
McMahon
Sirijatuphat
Qadir
Yulia
Waters.
Favipiravir has been officially adopted for early treatment in 10 countries (11 including non-government medical organizations). Submit updates/corrections.
Aug 18
Early, Late, PrEP, PEP Covid Analysis (Preprint) (meta analysis)
meta-analysis
Favipiravir for COVID-19: real-time meta analysis of 45 studies
Details   • Statistically significant improvements are seen for progression, recovery, and viral clearance. 24 studies from 24 independent teams in 16 different countries show statistically significant improvements in isolation (14 for the most ser..
Jun 29
Late Tawfik et al., Advances in Virology, doi:10.1155/2022/9240941
death, ↓96.5%, p<0.0001
Effectiveness of Early Favipiravir Therapy in Hospitalised COVID-19 Patients
Details   Retrospective 103 hospitalized patients in Saudi Arabia, showing lower mortality with favipiravir in unadjusted results, and greater efficacy for treatment within 3 days of admission.
Jun 14
Early McMahon et al., SSRN Electronic Journal, doi:10.2139/ssrn.4135325
oxygen, ↑1.0%, p=1.00
Favipiravir in Early Symptomatic COVID-19, A Randomised Placebo-Controlled Trial
Details   RCT with 99 favipiravir and 100 placebo patients in Australia, all except one being outpatients, showing no significant differences with treatment.
Jun 8
Early Sirijatuphat et al., medRxiv, doi:10.1101/2022.06.06.22275902
improv., ↓63.9%, p=0.0005
Early Treatment of Favipiravir in COVID-19 Patients Without Pneumonia: A Multicentre, Open-Labelled, Randomized Control Study
Details   RCT 93 patients in Thailand showing significantly faster clinical improvement with favipiravir treatment. 1800mg favipiravir bid day 1, 800mg bid 5-14 days until PCR-.
Jun 7
Early Usanma Koban et al., Bratislava Medical Journal, doi:10.4149/BLL_2022_082
viral+, ↓86.0%, p=0.03
The factors affecting the prolonged PCR positivity in COVID-19 patients
Details   Retrospective 126 patients in Turkey, showing lower risk of PCR+ at day 14 with favipiravir treatment.
May 23
Early Qadir et al., International Journal of Applied Sciences: Current and Future Research Trends, 13:1
death, ↓97.1%, p<0.0001
Efficacy of Favipiravir in the Treatment of Mild to Moderate COVID-19 Patients in Erbil: A Controlled Clinical Trial
Details   Prospective study with 125 favipiravir patients and 125 patients declining favipiravir treatment, showing lower mortality and improved recovery with treatment. All patients received vitamin C, D, and zinc. Favipiravir 3200mg day 1, follow..
May 17
Meta Lan et al., Expert Review of Clinical Pharmacology, doi:10.1080/17512433.2022.2078701 (meta analysis)
meta-analysis
Favipiravir-based treatment for outcomes of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials
Details   Systematic review and meta analysis of favipiravir RCTs, showing improved viral clearance and recovery, but no significant difference for mortality, ICU admission, or ventilation.
May 13
Late Rahman et al., Clinical Infection in Practice, doi:10.1016/j.clinpr.2022.100145
no improv., ↓89.5%, p=0.005
Safety and Efficacy of Favipiravir for the management of COVID-19 Patients: A Randomized Control Trial
Details   RCT hospitalized patients in Bangladesh, showing faster recovery and viral clearance with favipiravir treatment.
May 3
Early Reddy et al., International Journal of General Medicine, doi:10.2147/IJGM.S349241 Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting
Details   Prospective single-arm study of 1,083 patients receiving favipiravir in India, showing one death and no new safety issues.
Apr 22
Meta Hung et al., SSRN, doi:10.2139/ssrn.3889346 (meta analysis)
meta-analysis
The efficacy and adverse effects of favipiravir on COVID-19 patients: a systematic review and meta-analysis of published clinical trials and observational studies
Details   Systematic review and meta analysis of 17 favipiravir trials, showing improved viral clearance and recovery.
Apr 18
Review Hadj Hassine et al., Viruses, doi:10.3390/v14040841 (Review)
review
Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity
Details   Review of lethal mutagenesis for RNA viruses, as used by molnupiravir, favipiravir, and ribavirin. Authors note the potential for permanently modifying the genomes of patients while causing teratogenicity or embryotoxicity, and the potent..
Apr 8
Late Hafez et al., Antibiotics, doi:10.3390/antibiotics11040498
viral+, ↑3.1%, p=0.09
Antiviral Used among Non-Severe COVID-19 Cases in Relation to Time till Viral Clearance: A Retrospective Cohort Study
Details   Retrospective hospitalized patients in the United Arab Emirates, showing no significant difference in viral clearance with different combinations of HCQ, AZ, favipiravir, and lopinavir/ritonavir.
Mar 24
Late Shinada et al., Viruses, doi:10.3390/v14040670
hosp., ↓7.5%, p=0.84
Longitudinal Analysis of Neutralizing Potency against SARS-CoV-2 in the Recovered Patients after Treatment with or without Favipiravir
Details   Retrospective 17 COVID+ patients treated with favipiravir and 17 matched controls in Japan, showing faster viral clearance with treatment. Favipiravir 3600mg day one, 1600mg per day for up to 14 days.
Mar 23
Late AlQahtani et al., Scientific Reports, doi:10.1038/s41598-022-08794-w
death, ↑196.3%, p=1.00
Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease
Details   RCT with 54 favipiravir, 51 HCQ, and 52 SOC hospitalized patients in Bahrain, showing no significant differences. Viral clearance improved with both treatments, but did not reach statistical significance with the small sample size.
Mar 21
Early Tsuzuki et al., Infectious Diseases and Therapy, doi:10.1007/s40121-022-00617-9
death, ↓13.1%, p=0.59
Effectiveness of Favipiravir on Nonsevere, Early-Stage COVID-19 in Japan: A Large Observational Study Using the COVID-19 Registry Japan
Details   Retrospective database analysis of 7,654 hospitalized patients in Japan, showing no significant differences with favipiravir treatment. NCGM-G-003494-0.
Mar 17
Late Uyaroğlu et al., Acta Medica, doi:10.32552/2022.ActaMedica.719
death, ↓66.7%, p=1.00
Comparison of Favipiravir to Hydroxychloroquine Plus Azithromycin in the Treatment of Patients with Non-critical COVID-19: A Single-center, Retrospective, Propensity Score-matched Study
Details   PSM retrospective 260 late stage hospitalized COVID-19 pneumonia patients in Turkey, showing no significant difference between favipiravir and HCQ.
Mar 24
Late Hassaniazad et al., Journal of Medical Virology, doi:10.1002/jmv.27724
death, ↓67.7%, p=0.15
Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trial
Details   RCT comparing favipiravir and lopinavir/ritonavir, showing no significant differences. All patients received interferon-beta. Favipiravir 1600mg bid for the first day and 600mg bid for the following 4 days.
Mar 7
Late Yulia et al., Pathophysiology, doi:10.3390/pathophysiology29010009
death, ↓85.3%, p=0.05
Evaluation of Antibacterial and Antiviral Drug Effectiveness in COVID-19 Therapy: A Data-Driven Retrospective Approach
Details   Retrospective hospitalized patients in Indonesia, showing lower mortality and shorter hospitalization with favipiravir.
Mar 3
Late Cilli et al., Respiratory Medicine and Research, doi:10.1016/j.resmer.2022.100900
death, ↓37.5%, p=0.51
Characteristics and outcomes of COVID-19 patients with IPF: A multi-center retrospective study
Details   Retrospective 46 idiopathic pulmonary fibrosis patients with COVID-19 in Turkey, showing lower mortality with favipiravir in unadjusted results, without statistical significance.
Mar 1
Early Adhikari et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.12.109
no improv., ↑40.4%, p=0.57
Efficacy of Favipiravir in treatment of mild & moderate COVID-19 infection in Nepal: a multi-center, randomized, open-labelled, phase III clinical trial
Details   Preliminary report for an RCT in Nepal with 38 favipiravir patients and 32 control patients, showing no significant differences. There were no serious side effects.
Feb 28
Late Kurniyanto et al., Journal of Clinical Virology Plus, doi:10.1016/j.jcvp.2022.100068
death, ↓48.0%, p=0.21
Factors Associated with Death and ICU Referral among COVID-19 Patients Hospitalized in the Secondary Referral Academic Hospital in East Jakarta, Indonesia
Details   Retrospective 477 hospitalized patients in Indonesia, showing lower mortality with favipiravir in unadjusted results, not reaching statistical significance.
Feb 15
Late Al Mutair et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.01.013
death, ↓7.0%, p=0.49
Overview of Clinical Outcome and Therapeutic Effectiveness of Favipiravir in Patients with COVID-19 Admitted to Intensive Care Unit, Riyadh, Saudi Arabia
Details   Retrospective 269 favipiravir ICU patients in Saudi Arabia and 269 matched controls receiving different treatments, showing no significant difference.
Feb 15
Early Lowe et al., medRxiv, doi:10.1101/2022.02.11.22270775 (Preprint)
ICU, ↑196.3%, p=1.00
Favipiravir, lopinavir-ritonavir or combination therapy (FLARE): a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19
Details   240 patient RCT comparing favipiravir, favipiravir + LPV/r, LPV/r, and placebo, showing improved viral clearance with favipiravir. Efficacy was lower in the combined favipiravir + LPV/r arm, where plasma levels of favipiravir were lower. ..
Feb 1
Late Turan et al., The Brazilian Journal of Infectious Diseases, doi:10.1016/j.bjid.2022.102328
hosp., ↓79.4%, p=0.001
The effect of favipiravir versus hydroxychloroquine on clinical and laboratory findings in COVID-19 in healthcare workers
Details   Retrospective 237 low-risk healthcare workers in Turkey, 123 treated with favipiravir and 114 treated with HCQ, showing lower hospitalization and faster viral clearance with favipiravir, and similar improvement. This study is subject to s..
Jan 28
Review Waters et al., Environmental and Molecular Mutagenesis, doi:10.1002/em.22471 (Review)
review
Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir
Details   Review of antiviral nucleoside analog drugs that induce lethal mutagenesis, including molnupiravir and favipiravir, and the potential mutagenic risks to human DNA and human mitochondrial DNA. Author recommends monitoring for mutagenicity,..
Jan 12
In Vitro Unal et al., bioRxiv, doi:10.1101/2022.01.11.475889 (Preprint) (In Vitro)
In Vitro
Favipiravir, umifenovir and camostat mesylate: a comparative study against SARS-CoV-2
Details   In Vitro and In Silico study showing that the combination of favipiravir and umifenovir or camostat mesylate has greater antiviral efficacy than single drug treatment.
Jan 11
Early Bosaeed et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2021.12.026
ICU, ↑618.8%, p=0.11
Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicenter, placebo-controlled trial clinical trial
Details   RCT with 112 favipiravir and 119 control patients showing no significant differences in outcomes. Viral clearance and clinical recovery for patients treated within 48 hours was better than those treated later. NCT04464408.
Dec 7
2021
Late Finberg et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab56310
death, ↑200.0%, p=1.00
US201 Study: A Phase 2, Randomized Proof-of-Concept Trial of Favipiravir for the Treatment of COVID-19
Details   Small very late treatment RCT in the USA, with 25 favipiravir and 25 control patients, showing faster viral clearance with treatment. The benefit was only seen in patients <8 days from symptom onset. There were no significant differences ..
Nov 30
2021
Early Alattar et al., medRxiv, doi:10.1101/2021.11.29.21267042 (Preprint)
death, ↓33.3%, p=0.50
Favipiravir for the Treatment of Coronavirus Disease 2019; a propensity score-matched cohort study
Details   PSM retrospective with 1,493 patients, showing significantly improved viral clearance with favipiravir. There were no significant differences in clinical improvement or mortality. Mortality was lower (2.1% vs 3.1%), without statistical si..
Nov 24
2021
Early Holubar et al., Clinical Infectious Diseases, doi:10.1093/cid/ciac312 (preprint 11/24/2021)
hosp., ↓89.0%, p=0.06
Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial
Details   Small RCT 116 mITT patients in the USA, 59 treated with favipiravir, showing no significant differences with treatment.
Nov 19
2021
Late Chuah et al., Clinical Infectious Diseases, doi:10.1093/cid/ciab962
death, ↑1154.0%, p=0.08
Efficacy of Early Treatment with Favipiravir on Disease Progression among High Risk COVID-19 Patients: A Randomized, Open-Label Clinical Trial
Details   RCT 500 hospitalized patients in Malaysia, showing no significant differences with favipiravir treatment.
Nov 9
2021
Late Shenoy et al., medRxiv, doi:10.1101/2021.11.08.21265884 (Preprint)
death, ↑29.5%, p=0.54
Favipiravir In Adults with Moderate to Severe COVID-19: A Phase 3 Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial
Details   Late stage RCT with 353 hospitalized patients, showing no significant differences with favipiravir treatment overall, however a trend towards benefit was seen within patients treated relatively early, including a statistically significant..
Nov 1
2021
Late Damayanti et al., Kesmas: National Public Health Journal, doi:10.21109/kesmas.v16i4.5433
no recov., ↓54.5%, p=0.03
The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients in Bali, Indonesia
Details   Retrospective 192 hospitalized patients in Indonesia, 96 patients treated with favipiravir, showing improved recovery with treatment. Only the abstract is currently available.
Oct 5
2021
Late Atipornwanich et al., SSRN Electronic Journal, doi:10.2139/ssrn.3936499
death, ↓23.1%, p=0.66
Various Combinations of Favipiravir, Lopinavir-Ritonavir, Darunavir-Ritonavir, High-Dose Oseltamivir, and Hydroxychloroquine for the Treatment of COVID-19: A Randomized Controlled Trial (FIGHT-COVID-19 Study)
Details   RCT 200 moderate/severe patients in Thailand, showing significantly lower progression with favipiravir vs. oseltamivir. NCT04303299.
Sep 30
2021
Late Tabarsi et al., Iranian Journal of Pharmaceutical Research, doi:10.22037/ijpr.2021.115510.15401
death, ↓29.7%, p=0.70
Favipiravir Effects on the Control of Clinical Symptoms of Hospitalized COVID-19 Cases: An Experience with Iranian Formulated Dosage Form
Details   Small 62 patient late stage RCT in Iran comparing favipiravir and lopinavir/ritonavir, showing significant improvement in fever, cough, and dyspnea with favipiravir on day 5. There was no significant difference in mortality, ICU admission..
Sep 14
2021
Late Alotaibi et al., International Journal of General Medicine, 2021:14
death, ↓57.2%, p=0.05
Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study
Details   Retrospective hospitalized patients in Saudi Arabia, showing lower mortality with favipiravir compared to HCQ, not quite reaching statistical significance. Authors do not indicate the factors behind which therapy was chosen. May be subjec..
Sep 9
2021
Early Sawanpanyalert et al., Southeast Asian Journal of Tropical Medicine and Public Health, 52:4
progression, ↓68.0%, p=0.003
Assessment of outcomes following implementation of antiviral treatment guidelines for COVID-19 during the first wave in Thailand
Details   Retrospective 744 hospitalized patients in Thailand, showing lower risk of a poor outcome for favipiravir treatment within 4 days of symptom onset. Early treatment with CQ/HCQ and lopinavir/ritonavir or darunavir/ritonavir also showed low..
Sep 2
2021
Late Chen et al., Frontiers in Pharmacology, doi:10.3389/fphar.2021.683296
ICU, ↑3.4%, p=1.00
Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial
Details   Very late stage (9 days from symptom onset) RCT with 116 favipiravir patients and 120 arbidol patients in China, showing no significant difference in clinical recovery (relief of fever and cough, respiratory frequency ≤24 times/min, and o..
Aug 31
2021
Late Kulzhanova et al.,
no improv., ↓88.0%, p<0.0001
Clinical efficacy of the antiviral drug favipiravir in the complex treatment of patients with COVID-19 coronavirus infection
Details   Retrospective 40 favipiravir patients in Kazakhstan and 40 controls, showing faster recovery and viral clearance with treatment.
Aug 28
2021
Late Assiri et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2021.08.030
death, ↑79.3%, p=0.50
COVID-19 related treatment and outcomes among COVID-19 ICU patients: A retrospective cohort study
Details   Retrospective 118 ICU patients in Saudi Arabia showing no significant differences in unadjusted results with zinc, vitamin D, and favipiravir treatment.
Aug 27
2021
Late Shinkai et al., Infectious Diseases and Therapy, doi:10.1007/s40121-021-00517-4
imp. time, ↓37.1%, p=0.01
Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial
Details   RCT 156 patients in Japan, 107 treated with favipiravir, showing significant improvement in a composite outcome defined as the time to improvement in temperature, SpO2, CT findings, and recovery to PCR-.
Aug 24
2021
Late Almoosa et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2021.08.022
death, ↑42.3%, p=0.10
Favipiravir versus Standard of Care in Patients with Severe COVID-19 Infections: A Retrospective Comparative Study
Details   Retrospective 226 COVID-19 pneumonia patients, 110 treated with favipiravir, showing higher mortality (p=0.1) and ICU admission (p=0.02) with treatment in multivariate analysis.
May 19
2021
Late Alamer et al., Current Medical Research and Opinion, doi:10.1080/03007995.2021.1920900
death, ↑56.0%, p=0.26
Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis
Details   Retrospective 234 favipiravir and 223 control patients in Saudi Arabia, showing shorter time to discharge and lower progression to ventilation, but no significant difference in mortality.
May 5
2021
Review Zhirnov et al., Journal of microbiology, epidemiology and immunobiology, doi:10.36233/0372-9311-114 (Review)
review
Favipiravir: the hidden threat of mutagenic action
Details   Review of the mutagenic effect of favipiravir and associated concerns.
Apr 29
2021
Late Aghajani et al., Journal of Medical Virology, doi:10.1002/jmv.27053
death, ↓26.1%, p=0.28
Decreased In-Hospital Mortality Associated with Aspirin Administration in Hospitalized Patients Due to Severe COVID-19
Details   Retrospective 991 hospitalized patients in Iran focusing on aspirin use but also showing results for HCQ, remdesivir, and favipiravir.
Apr 21
2021
Late Zhao et al., International Immunopharmacology, doi:10.1016/j.intimp.2021.107702
viral+, ↓59.0%, p=0.06
Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: a multicenter, open-label, randomized trial
Details   RCT with 55 patients (36 favipiravir, 19 control) who were PCR+ after recovery, showing improved viral clearance with treatment.
Apr 19
2021
Late Favipiravir Observational Study Group, Fujita Health University (Preprint) Favipiravir Observational Study Interim Report 3
Details   Retrospective analysis of favipiravir use in 10,986 hospitalized patients, including analysis of changes in clinical status and side effects. Common adverse events were uric acid level increase and liver function enzyme increase. Authors ..
Apr 17
2021
Early Fujii et al., Journal of Infection and Chemotherapy, doi:10.1016/j.jiac.2021.04.013 Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients
Details   Retrospective 41 favipiravir patients finding that early treatment was more successful.
Mar 11
2021
Late Solaymani-Dodaran et al., International Immunopharmacology, doi:10.1016/j.intimp.2021.107522
death, ↑19.2%, p=0.54
Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia
Details   RCT late stage patients (median SpO2 89), 193 treated with favipiravir, 187 with lopinavir/ritonavir, showing no significant differences in mortality, intubation, or ICU admission.
Mar 8
2021
Late Fateh et al., medRxiv, doi:10.1101/2021.03.05.21251351 (Preprint) A single-center retrospective cohort study of Covid-19 medications: Remdesivir, Favipiravir, Methylprednisolone, Dexamethasone, and Interferon β1a and their combinations
Details   Retrospective 324 hospitalized patients in Iran reporting on the use Remdesivir, Favipiravir, Methylprednisolone, Dexamethasone, and Interferon β1a and their combinations. There is no control group in this study.
Feb 4
2021
Early, Late Uçan et al., Research Square, doi:10.21203/rs.3.rs-175340/v1 (Preprint) Benefits of Treatment With Favipiravir in Hospitalized Patients for COVID-19: a Retrospective Observational Case-control Study
Details   Retrospective 144 COVID-19 patients in Turkey, one group receiving FPV after a mean of 4.7 days, a second group after a mean of 8.6 days, and all groups receiving HCQ. No improvement in clinical outcomes was seen with the addition of FPV,..
Jan 25
2021
Early Dabbous et al., Archives of Virology, doi:10.1007/s00705-021-04956-9 Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study
Details   This study was retracted.
Jan 14
2021
Early Karatas et al., Research Square, doi:10.21203/rs.3.rs-142868/v1 (Preprint) Early Onset Favipiravir Saves Lives
Details   Retrospective 180 hospitalized patients showing lower mortality when Favipiravir is given earlier. 17% of patients given Favipiravir within 3 days died, compared to 38% when given after 3 days.
Nov 17
2020
Late Doi et al., Antimicrobial Agents and Chemotherapy, doi:10.1128/AAC.01897-20 A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19
Details   Small RCT comparing late and very late (7 and 14 days from fever onset) favipiravir. Viral clearance was non-statistically significantly improved with relatively early treatment. There was a reduction in time to defervescence, and a signi..
Nov 16
2020
Early Udwadia et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.142
recov. time, ↓40.0%, p=0.03
Efficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial
Details   RCT with 75 favipiravir patients and 75 control patients showing reduced time to clinical cure and reduced time of viral shedding.
Nov 9
2020
Late Khamis et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.008
death, ↓14.8%, p=1.00
Randomized Controlled Open Label Trial on the Use of Favipiravir Combined with Inhaled Interferon beta-1b in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia
Details   Small 89 patient RCT comparing favipiravir and inhaled interferon with HCQ for moderate to severe COVID-19 pneumonia, not finding significant differences. There was no control group.
Nov 5
2020
Late Pushkar et al., NCT04542694 (Preprint)
no recov., ↓14.1%, p=0.06
Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19
Details   RCT 200 patients showing improvements in clinical recovery and viral clearance with favipiravir. There is no paper available but results are posted in clinicaltrials.gov.
Oct 26
2020
Early Ruzhentsova et al., SSRN, doi:10.2139/ssrn.3696907 (Preprint)
hosp., ↓6.0%, p=0.49
Phase 3 Trial of Coronavir (Favipiravir) in Patients with Mild to Moderate COVID-19
Details   RCT 168 patients, 112 receiving favipiravir and 56 SOC, showing shorter time to clinical improvement and faster viral clearance with favipiravir.
Oct 25
2020
Late Lou et al., European Journal of Pharmaceutical Sciences, doi:10.1016/j.ejps.2020.105631
ICU, ↑422.2%, p=0.21
Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial
Details   Small late stage RCT with 10 favipiravir, 10 baloxavir marboxil, and 10 control patients in China, showing no significant differences. ChiCTR 2000029544.
Sep 30
2020
Late Zhaao et al., Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2020.110825 Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size
Details   Small study with 14 combined favipiravir/tocilizumab, 7 favipiravir, and 5 tocilizumab patients suggesting that tocilizumab combined with or without favipiravir can improve pulmonary inflammation and inhibit progression.
Aug 9
2020
Late Ivashchenko et al., Clin. Infect. Dis., doi:10.1093/cid/ciaa1176
viral+, ↓46.4%, p=0.03
AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
Details   Intermin results for a small RCT with 40 favipiravir and 20 control patients showing faster viral clearance with favipiravir. There is limited data in this report to evaluate the results. The report indicates that 75% of the control group..
Jun 19
2020
Animal Kaptein et al., bioRxiv, doi:10.1101/2020.06.19.159053
animal study
Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity
Details   Animal study with Syrian hamsters, showing antiviral activity with favipiravir.
Mar 18
2020
Late Cai et al., Engineering, doi:10.1016/j.eng.2020.03.007
pneumonia, ↓68.7%, p=0.04
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Details   Comparison of 35 FPV patients and 35 LPV/RTV patients, showing significant improvements in chest CT and faster viral clearance with FPV.
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit